During the second quarter of 2026, two healthcare-focused funds managed by Zhongou Fund's Investment Director, Ge Lan, outperformed their benchmarks against the market trend.
In her recently disclosed second-quarter report, Junshi BIO (01877) made its first appearance among the top ten holdings of the funds. Concurrently, Sichuan Kelun Pharmaceutical Co.,Ltd. (002422) received a substantial increase in its position within the portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments